NR1I2 and breast cancer: In this study, we used SR12813, a potent and selective agonist of hPXR, to upregulate and activate the PXR protein in breast cancer cells, and analyzed the correlation between PXR and drug resistance in breast cancer, this study was designed to explore the formation mechanism of drug resistance of breast cancer cells and provide theoretical basis for clinical chemotherapy.